Virax Biolabs Sets March 11, 2026 AGM to Vote on Reverse Share Split and New Equity Plan

The latest announcement is out from Virax Biolabs Group Ltd. Class A ( (VRAX) ).

On January 30, 2026, Virax Biolabs Group Limited called its 2025 Annual General Meeting of shareholders to be held on March 11, 2026, in Glasgow, setting January 12, 2026 as the record date for voting. At the AGM, shareholders will be asked to ratify the appointment of Reliant CPAs PC as auditor for the fiscal year ending March 31, 2026, reappoint five incumbent directors, authorize a reverse share consolidation at a ratio between 10-for-1 and 15-for-1 with related charter amendments, approve a new 2026 Equity Incentive Plan including a UK sub-plan, and permit adjournment of the meeting if additional time is needed to secure votes, signaling a broad corporate housekeeping and capital-structure adjustment effort with implications for the company’s share count, governance framework and employee compensation schemes.

The most recent analyst rating on (VRAX) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Virax Biolabs Group Ltd. Class A stock, see the VRAX Stock Forecast page.

More about Virax Biolabs Group Ltd. Class A

Virax Biolabs Group Limited is a Cayman Islands–incorporated life sciences company based in the United Kingdom, operating in the biotechnology and diagnostics sector. The company focuses on developing and commercializing diagnostic and related solutions, with its shares listed on Nasdaq, and it serves global healthcare and investor markets interested in infectious disease and immunology-related technologies.

Average Trading Volume: 5,275,987

Technical Sentiment Signal: Sell

Current Market Cap: $2.15M

For detailed information about VRAX stock, go to TipRanks’ Stock Analysis page.